Massachusetts Financial Services CO Coherus Bio Sciences, Inc. Transaction History

Massachusetts Financial Services CO

$320 Billion
Q3 2024

A detailed history of Massachusetts Financial Services CO transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 99,111 shares of CHRS stock, worth $168,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,111

Previous 101,511 2.36%

Holding current value

$168,488

Previous $175,000 41.14%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$0.99 - $1.8 $2,376 - $4,320	-2,400 Reduced 2.36%	99,111 $103,000
Q2 2024 Aug 09, 2024	BUY	$1.58 - $2.51 $5,386 - $8,556	3,409 Added 3.47%	101,511 $175,000
Q1 2024 May 14, 2024	SELL	$2.02 - $3.14 $436 - $678	-216 Reduced 0.22%	98,102 $234,000
Q4 2023 Feb 08, 2024	SELL	$1.59 - $3.85 $4,935 - $11,950	-3,104 Reduced 3.06%	98,318 $327,000
Q3 2023 Nov 08, 2023	SELL	$3.74 - $5.45 $14,537 - $21,184	-3,887 Reduced 3.69%	101,422 $379,000
Q2 2023 Aug 09, 2023	SELL	$3.79 - $8.3 $9,395 - $20,575	-2,479 Reduced 2.3%	105,309 $449,000
Q1 2023 May 10, 2023	SELL	$5.89 - $10.52 $17,946 - $32,054	-3,047 Reduced 2.75%	107,788 $737,000
Q4 2022 Feb 13, 2023	BUY	$5.69 - $10.07 $13,354 - $23,634	2,347 Added 2.16%	110,835 $877,000
Q3 2022 Nov 09, 2022	SELL	$7.17 - $13.87 $7,083 - $13,703	-988 Reduced 0.9%	108,488 $1.04 Million
Q2 2022 Aug 09, 2022	BUY	$5.86 - $13.23 $3,234 - $7,302	552 Added 0.51%	109,476 $793,000
Q1 2022 May 11, 2022	BUY	$10.92 - $16.41 $12,230 - $18,379	1,120 Added 1.04%	108,924 $1.41 Million
Q4 2021 Feb 10, 2022	SELL	$15.81 - $18.99 $34,513 - $41,455	-2,183 Reduced 1.98%	107,804 $1.72 Million
Q3 2021 Nov 10, 2021	SELL	$12.68 - $17.79 $18,309 - $25,688	-1,444 Reduced 1.3%	109,987 $1.77 Million
Q2 2021 Aug 13, 2021	BUY	$12.95 - $15.41 $12,380 - $14,731	956 Added 0.87%	111,431 $1.54 Million
Q1 2021 May 13, 2021	SELL	$14.42 - $21.39 $188,786 - $280,037	-13,092 Reduced 10.6%	110,475 $1.61 Million
Q4 2020 Feb 12, 2021	SELL	$16.56 - $18.94 $20,484 - $23,428	-1,237 Reduced 0.99%	123,567 $2.15 Million
Q3 2020 Nov 12, 2020	SELL	$17.41 - $19.89 $85,117 - $97,242	-4,889 Reduced 3.77%	124,804 $2.29 Million
Q2 2020 Aug 11, 2020	SELL	$14.43 - $19.16 $47,705 - $63,342	-3,306 Reduced 2.49%	129,693 $2.32 Million
Q1 2020 May 14, 2020	BUY	$11.67 - $22.53 $245,653 - $474,256	21,050 Added 18.8%	132,999 $2.16 Million
Q4 2019 Feb 13, 2020	BUY	$16.33 - $21.37 $1.55 Million - $2.02 Million	94,733 Added 550.26%	111,949 $2.02 Million
Q3 2019 Nov 05, 2019	BUY	$16.3 - $23.37 $280,620 - $402,337	17,216 New	17,216 $349,000

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $132M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Account

Massachusetts Financial Services CO Coherus Bio Sciences, Inc. Transaction History